UCLA to host 9th Annual Brain Tumor Conference
April 10 - 11, 2009
REGISTRATION INFORMATION INSIDE

Researchers help predict who benefits from use of Bevacizumab (Avastin™)

Bortezomib (VELCADE), Temozolomide trial for newly diagnosed GBM patients to begin at UCLA

Art of the Brain Gala raises hope & expectations for Brain Cancer Research

Ivy Foundation awards funding for novel Molecular Diagnostic Tools
UCLA Researchers help predict who benefits from use of Bevacizumab (Avastin™)

Two research articles from the UCLA Neuro-Oncology Program are scheduled to be published and will help define which patients might have the greatest likelihood of responding to bevacizumab for the treatment of recurrent Glioblastoma (GBM) brain tumors.

The first article will be published in the journal Neurology in March 2009. The study, lead by Dr. Leia Nghiemphu, evaluated two carefully selected cohorts of patients: those treated with bevacizumab for recurrent Glioblastoma and those never treated with bevacizumab but receiving standard therapies or other experimental therapies for recurrent Glioblastoma.

Dr Nghiemphu’s first finding was that patients who received bevacizumab did better than those who never received the agent with regard to progression free survival and overall survival. This finding was not surprising given the success of bevacizumab in several single institution and multi-institutions studies. What was surprising was that the majority of the benefit was seen in patients over 55 years of age. The reason for this seems to be, in part, related to the fact that VEGF A, the target for bevacizumab, is expressed at a higher level in patients who are over 55. “This is important because for the first time, with a therapy, we are seeing a benefit of a therapy to those who are older,” said Dr. Cloughesy Director of the Neuro-Oncology Program at UCLA. “Typically those patients who are over 55 years of age have the poorest prognosis,” stated Cloughesy, “but that appears to be changing now with the success of anti-VEGF therapy such as bevacizumab.”

Given this insight, Dr. Nghiemphu is planning to run a study in newly diagnosed patients with Glioblastoma who are over 70 years of age with Bevacizumab and Temozolomide in an effort to hold off delivering radiation therapy. “The use of radiation therapy in the elderly has been thought to be quite difficult to tolerate. This approach might give us the ability to successfully treat the elderly with Glioblastoma without radiation therapy,” states Dr. Nghiemphu, “this approach might provide the patient with improved control of the disease, maintain cognitive function and thereby improve quality of life.” This study is planned to open by June 2009.

The second investigation was lead by Dr. Whitney Pope, Assistant Professor of Radiology at UCLA. This article is scheduled to be published in the prominent journal Radiology in spring 2009. This work focuses on how to identify patients who have a greater likelihood of responding to Bevacizumab based upon the pretreatment imaging features. Dr. Pope used a magnetic resonance imaging (MRI) modality called apparent diffusion coefficient (ADC) imaging. He evaluated the ADC voxels with in the contrast enhancing area he analyzed the data by creating a histogram of the data. When two features of the histogram were present, over 50% of the patient were without tumor growth at 6 months but only 10% in those with out those features. “The beauty of this approach is that the histogram is developed in an automated way making this work applicable to any center,” stated Dr. Pope. “This data will soon be validated in a larger multi-center sample. “If this approach continues show strong predictability, it may have a huge impact on patient care and future trials,” stated Dr. Cloughesy.
Choosing to participate in a clinical trial is an important personal decision. It is often helpful to talk to a physician, family members, or friends about deciding to join a trial. After identifying some trial options, the next step is to contact the study research staff and ask questions about specific trials.

<table>
<thead>
<tr>
<th>Trial Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>OSI3781s</td>
<td>A Phase I/II, Dual-Center, Open-Label Trial of the Safety and Efficacy of TarcevaTM (Erlotinib Hydrochloride) Plus Sirolimus in Patients with Recurrent Malignant Glioma Not on P450-Inducing Anti-Epileptics.</td>
</tr>
<tr>
<td>AVF3770s</td>
<td>Phase II Trial of Bevacizumab in Combination with Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients with Newly-Diagnosed Glioblastoma Multiforme.</td>
</tr>
<tr>
<td>(Molecular D-001)</td>
<td>Molecular Genetic Characterization of Human Brain Tumors.</td>
</tr>
<tr>
<td>(Exelixis XL765-002)</td>
<td>A Phase I Dose-Escalation Study of XL765 in Combination with Temozolomide in Subjects with Malignant Glioma.</td>
</tr>
<tr>
<td>(Novartis-RAD001C2410)</td>
<td>A Phase II Trial of RAD001 in Patients with Recurrent Glioblastoma Multiforme.</td>
</tr>
<tr>
<td>(NABTC 04-03)</td>
<td>A Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in Combination with Temozolomide in Patients with Malignant Gliomas.</td>
</tr>
<tr>
<td>(NABTC 05-02)</td>
<td>A Phase I/II Studies of Bay 43-9006 (sorafenib) in Combination with OSI-774 (erlotinib), R115777 (tipifarnib) or CCI-779 (temsirolimus) in Patients with Recurrent Glioblastoma Multiforme or Gliosarcoma.</td>
</tr>
<tr>
<td>(NABTC 07-01)</td>
<td>Phase I Trial of Aflibercept (VEGF Trap) with Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients with Malignant Gliomas.</td>
</tr>
</tbody>
</table>

For more information about any of the UCLA Neuro-Oncology Program’s clinical trials listed, please contact Emese Filka, Clinical Trials Coordinator, at (310) 794-3521

Clinical Trials are carried out in phases, each designed to find out certain information. Patients may be eligible for studies in different phases depending on their general condition and the type and stage of their cancer. More patients take part in the later phases of studies than in the earlier ones.

In a Phase I study, a new research treatment is given to a small number of patients. The researchers must find the best way to give a new treatment and how much of it can be given safely. They watch carefully for any harmful side effects. The research treatment has been well tested in laboratory and animal studies but no one knows how patients will react. Phase I studies may involve significant risks for this reason. They are offered only to patients whose cancer has spread and who would not be helped by other known treatments. Phase I treatments may produce anticancer effects, and some patients have been helped by these treatments.

Phase II studies determine the effect of a research treatment on various types of cancer. Each new phase of a clinical trial depends on and builds on information from an earlier phase. If a treatment has shown activity against cancer in Phase II, it moves to Phase III. Here it is compared with standard treatment to see which is more effective. Often researchers use standard therapy as the base to design new, hopefully better treatments.

Phase III, the new treatment is directly compared to the old one.

In Phase IV studies, the new research treatment becomes part of standard treatment in patient care. For example, a new drug that has been found effective in a clinical trial may then be used together with other effective drugs or with surgery and/or radiation therapy.
Bortezomib (VELCADE), Temozolomide trial for newly diagnosed GBM patients to begin at UCLA

UCLA Neuro-Oncology is set to offer a new investigator-initiated Phase II study. The new study will seek to examine the efficacy and safety of the combination therapy of bortezomib (VELCADE), temozolomide, and radiation therapy followed by bortezomib and temozolomide after completion of radiation.

The study, supported by Millenium Pharmaceuticals, will be an open-label study for newly-diagnosed adult patients with glioblastoma that have not received therapy other than surgery.

Enrollment is expected to begin in April, 2009 with an estimated enrollment of 70 patients over a two year period. “The objectives of the study are to estimate the overall and progression-free survival in patients with a newly-diagnosed glioblastoma [primary brain tumor],” Dr Albert Lai of the UCLA Neuro-Oncology Program, “The trial will attempt to use a combination therapy approach after radiation to prevent the tumor from recurring.” The combination of bortezomib (VELCADE), temozolomide will last 24 cycles (~2 years) following radiation or until progression is detected.

A key enrollment inclusion criteria for eligible patients is the collection of frozen and paraffinized tumor tissue. These resources will provide samples for correlative studies aimed at understanding molecular features that may predict a response to treatment.

About Bortezomib (VELCADE)

Bortezomib is a reversible inhibitor of the proteasome, which plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the proteasome can affect multiple signaling cascades within the cell, particularly NF-kB signaling. Bortezomib has gained FDA approval for myeloma in the relapsed and frontline settings and in relapsed mantle cell lymphoma. There currently is some preclinical evidence demonstrating activity of bortezomib against glioblastoma.

Trial Details

Patients will receive 1.3 mg/m2 bortezomib IV on days 1, 4, 8, 11, 29, 32, 36, and 39 and oral temozolomide 75 mg/m2 daily during radiation. Bortezomib will be administered beginning on the first day of radiation with temozolomide. External beam fractionated regional radiation will be given on consecutive week days at 200 cGy daily doses to a total dose of 6000 cGy.

After a 2-6 week rest (for temozolomide and bortezomib) following completion of radiation therapy, a maintenance phase (post-RT) of temozolomide will be restarted at 150-200 mg/ m2/day for 5 days out of every 28. Also, bortezomib at 1.3 mg/ m² will given on days 1, 4, 8, and 11 of a 28 day cycle commencing on the first day of temozolomide.

Treatment with bortezomib and temozolomide will continue for 24 additional 28 day cycles from radiation therapy if there is no evidence of progression. At that time, both bortezomib and temozolomide will be stopped if there is no evidence of disease progression.

Some of the anticipated side effects include lowering of blood counts, fatigue, nausea, and peripheral neuropathy.

For more information about this trial please contact Emese Filka, Clinical Trials Coordinator, at (310) 794-3521
UCLA Neuro-Oncology to host 9th Annual Brain Tumor Conference April 10-11, 2009

Join brain cancer survivors, family members, friends and health care professionals at the Ninth Annual Brain Tumor Conference, hosted by the UCLA Neuro-Oncology Program. This FREE conference will offer participants the opportunity to hear leading healthcare professionals speak about the latest treatments for brain tumors. Through this conference, the Neuro-Oncology Program promotes the sharing of information and experience between brain tumor survivors, their families, friends and health care professionals.

Event Details

<table>
<thead>
<tr>
<th>Date</th>
<th>April 10th &amp; 11th 8am - 5pm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Location</td>
<td>UCLA Covel Commons</td>
</tr>
<tr>
<td></td>
<td>Grand Horizons Room</td>
</tr>
<tr>
<td></td>
<td>330 DeNeve Drive, 3rd Floor</td>
</tr>
<tr>
<td></td>
<td>Los Angeles, CA 90095</td>
</tr>
<tr>
<td>Event Cost</td>
<td>FREE</td>
</tr>
</tbody>
</table>

Pre-registration is required. Early registration is encouraged as conference space and materials are limited.

HOW TO REGISTER

Online: Visit www.neurooncology.ucla.edu and fill out the secure registration form by April 7, 2009.

Mail: Fill out the enclosed registration form and return by April 6, 2009 to: UCLA Neuro-Oncology

710 Westwood Plaza
Reed Bldg RM 1-230
Los Angeles, CA 90095

Fax: Or fax the enclosed registration form to (310) 267-1292 by April 7, 2009

HOTEL ACCOMMODATIONS

There are several surrounding hotels available for accommodation during the conference.

UCLA Guest House (310) 825-2923
Hilgard House (310) 208-3945
Double Tree Hotel (310) 475-8711
The Claremont Hotel (310) 208-5957
Angeleno Hotel (310) 476-6411

For a more detailed map, expanded driving directions, updated conference schedule and events please visit www.neurooncology.ucla.edu.

Directions To Event

* Take the San Diego Freeway (I-405).
* Exit on Sunset Blvd.
* EAST on Sunset Blvd. and enter the campus by turning RIGHT on Bellagio Drive. Proceed to Stop sign at the top of the hill. Turn LEFT at the stop sign onto DeNeve Dr.
* Proceed 3/10 of a mile down the hill to the PSV (Sunset Village) parking structure.
* Purchase a parking permit for the Sunset Village (PSV) lot from the attendant at the gate. (Attendant will only be at this gate until 12:00pm. After 12pm, please purchase a permit from the Parking Information Kiosk at Parking Structure 4) Park in any UNRESTRICTED space. (Parking overflow may be directed to park at Parking Structure 7) Parking permits are $9 per day and are good for only one lot.
* In the Sunset Village (PSV) parking structure, take the elevator or stairs (located in the southwest corner of the parking garage) to the Lobby Level (L). The Covel Commons building will be directly in front of you as you exit the elevator. Follow signs to the conference.
UCLA 9th Annual Brain Tumor Conference
Schedule of Events

FRIDAY, APRIL 10, 2009:
GENERAL SESSIONS

8:00 am  Registration & Continental Breakfast

9:00 am  Welcome Note & Overview
    Dr. Timothy F. Cloughesy
    Professor & Director, UCLA NeuroOncology

10:00 am  Neurosurgery Techniques & Image Guided Surgery
    Dr. Bob Shafa
    UCLA Neurosurgery

11:00 am  Radiation Treatments
    Dr. Michael Selch
    UCLA Clinical Radiation Oncology

    Stereotactic Radiotherapy
    Dr. Antonio DeSalles
    Professor, UCLA Neurosurgery

12:00 am  LUNCH

1:00 pm  Chemotherapy & Biological Agents
    Dr. Albert Lai
    Asst Professor, UCLA Dept of Neurology

2:00 pm  Understanding Neuropathology
    Dr. Paul Mischel
    Professor, UCLA Pathology & Lab Medicine

3:00 pm  Experimental Therapies: Clinical Trials & Immunotherapy
    Dr. Leia Nghiemph

4:00 pm  Diagnostic Tools (Imaging)
    Dr. Whitney Pope
    Asst Professor, UCLA Radiological Science

CONSULTATION SESSIONS ON 4/10

Participants will also have the opportunity to make appointments for free 15-minute consult sessions with a participating physician regarding on-going care, neurosurgery, radiation treatments, pathology, symptom management, etc. Social workers and legal advocates will also be available for consultation. Sign-ups are available only the day of event. Appointments are limited so please arrive early to reserve an appointment time.

SATURDAY, APRIL 11, 2009:
BREAKOUT SESSIONS

8:00 am  Registration & Continental Breakfast

9:00 am  SESSION 1
    A. Understanding Language Impairments
        Andrew Erman, MA/CCC-SLP, UCLA Speech Pathology
    B. Legal Issues I: Employment & Benefits
        Joanna Morales, Esq. -Cancer Legal Res. Center
    C. Complementary Medicine Approaches
        TBA
    D. Tumor Type: Brain Metastasis
        Dr. Timothy Cloughesy

10:00 am  SESSION 2
    A. Symptom Management
        Stacey Green NP, UCLA Neuro-Oncology Program
    B. End of Life Issues
        Dr. Michael Galindo, UCLA Dept of Medicine
    C. Integrating Psychosocial Support Into Treatment - The "Patient Active" Approach
        Malcolm Schultz, The Wellness Community - W. LA

11:00 am  SESSION 3
    A. Neuropsychology and Brain Tumors
        Patricia Walshaw, PhD, UCLA Semel Institute
    B. Legal Issues II:
        Joanna Morales, Esq.
    C. Understanding the Family Experience
        Cheryl Abe LCSW, UCLA Oncology Center
        Pam Hoff LCSW, UCLA Dept of Radiation Oncology

12:00 am  LUNCH

12:45 pm  SESSION 4
    A. Seizure Management
        Nanette Fong NP, UCLA Neuro-Oncology Program
    B. Nutrition
        Carolyn Katzin, Certified Nutrition Specialist
    C. Understanding Clinical Trials
        Dr. Leia Nghiemph, UCLA Neuro-Oncology Program

1:45 pm  SESSION 5
    A. Tumor Type: Glioblastoma & Anaplastic Astrocytoma
        Dr. Timothy Cloughesy
    B. Tumor Type: Oligodendroglioma & Low Grade Tumors
        Dr. Albert Lai
    C. Tumor Type: Meningioma
        Dr. Richard Green, Dir. - Kaiser LA Neuro-Oncology
    D. Tumor Type: Rare Tumors
        Dr. Leia Nghiemph, UCLA Neuro-Oncology
UCLA CONFERENCE REGISTRATION FORM

Please complete this form and return to: UCLA Brain Tumor Conference C/O Luzianne Dugenia Fernandez 710 Westwood Plaza, Reed Building #1230 Los Angeles, CA 90095 If registering by fax, do NOT send form by mail. Fax: 310.267.1292 Phone: 310.206.3610 Online Registration: www.neurooncology.ucla.edu Registration deadline by fax or online is April 7th Mailed forms must be postmarked by April 6th

If registering family member(s) or companion(s), please complete a separate Registration Form for each attendee. Send all forms together to the address listed above.

FIRST NAME_______________________ LAST NAME___________________________
TITLE _____________________________ ORGANIZATION______________________________________
ADDRESS________________________________________________________________________________
CITY _____________________________________ STATE___________________ ZIP CODE_____
DAY TIME PHONE___________________________ EVENING PHONE____________________________
FAX___________________________________ EMAIL ___________________________________________

PLEASE INDICATE WHICH WORKSHOP(S) YOU PLAN TO ATTEND FOR EACH DAY

FRIDAY, APRIL 10, 2009: GENERAL SESSIONS
_____9:15-10am: Overview of Brain Tumors
_____10-11am: Neurosurgery Techniques
_____11-12pm: Radiation Treatments
_____1-2pm: Chemotherapies & Biological Agents
_____2-3pm: Understanding Neuropathology
_____3-4pm: Experimental Therapies
_____4-5pm: Diagnostic Imaging Tools

SATURDAY, APRIL 11 2009: BREAKOUT SESSIONS
SESSION 1: 9:00 -9:45am
_____ A. Language Impairments
_____ B. Legal Issues I
_____ C. Complementary Medicine
_____ D. Tumor Type: Brain Metastasis

SESSION 2: 10:00-10:45am
_____ A. Symptom Management
_____ B. End of Life Issues
_____ C. Psychosocial Support

SESSION 3: 11:00-11:45am
_____ A. Neuropsych & Brain Tumors
_____ B. Legal Issues II
_____ C. Understanding Family Exp.

SESSION 4: 12:45-1:30pm
_____ A. Seizure Management
_____ B. Nutrition
_____ C. Understanding Clinical Trials

SESSION 5: 1:45-2:30pm
_____ A. Tumor Type: GBM/AA
_____ B. Tumor Type: Low Grade & Meningiomas
_____ C. Tumor Type: Rare Tumors Oligodendrogliomas

Do you require a vegetarian meal? Yes No
Do you require special assistance? Yes No Please specify: ______________________________________
Currently receiving treatment at UCLA? Yes No Type of brain tumor? _________________________________
How did you hear about this conference? _________________________________________________________________
Art of the Brain Ninth Annual Gala - Rasies Hope & Expectations for a Cure.

Art of the Brain, a non-profit organization of the UCLA Foundation supporting the UCLA Neuro-Oncology Program, held its annual gala fundraiser on Saturday, October 4, 2008. The annual gala spotlights the talent, courage and strength of brain cancer survivors and raises funds for brain cancer research headed by Dr. Timothy Cloughesy of the UCLA Neuro-Oncology Program. This event was dedicated to Adam Balch.

The Ninth Annual Gala, entitled “The Light of Legacy, Laughter and Land,” was held at Schoenberg Hall Auditorium on the UCLA campus. Five hundred brain cancer research supporters attended the event. Jason Barry of the Phoenix, Arizona CBS affiliate was Master of Ceremonies for the sixth straight year. Barry’s father had passed away from brain cancer several years ago.

This year’s program included a performance by Hamilton High School Academy of Music’s Vocal Jazz Ensemble, led by John Hamilton. The Vocal Jazz Ensemble sang songs of light sharing a sense of optimism and encouragement. One number they performed included “When You’re Smiling,” which was made famous by Louis Armstrong. The Vocal Jazz Ensemble is part of the Hamilton Academy of Music Magnet, a magnet program of Los Angeles’ Hamilton High School. The Academy of Music is renowned for their talented pool of student musicians and has been recognized as a Grammy Signature School by National Academy of Recording Arts and Sciences.

Also performing at the Gala was String Theory, an eclectic musical group co-founded by Luke and Holly Rothschild. String Theory has been a supporter Art of the Brain for the past few years. They first performed at the annual Art of the Brain Gala in 2007. They returned to perform once again before the crowd of fellow brain cancer research supporters using their unique style of visual music. String Theory is known for utilizing their performance space and incorporating their musical instruments with the environment, accompanied with dance, bringing a unique blend of music and art.

Without the support of friends and donors, Art of the Brain would not be able to fund important brain cancer research. One person vital to the success of Art of the Brain reaching its goals is Geoffry Oblath, Esq. He was awarded the Judi Kaufman Founder’s Responsibility Award at the event for his commitment to fundraising and helping to find a cure for brain cancer. Mr. Oblath, an entertainment lawyer and senior partner at Jackoway Tyerman Wertheimer Austen Mandelbaum Morris & Klein of Los Angeles, has been an avid supporter of Art of the Brain since its inception, offering support in many ways. He has made efforts to educate the community about Dr. Cloughesy and his colleagues’ research breakthroughs. He also has expanded the reach of Art of the Brain as the major community
fundraising and educational program of the UCLA Neuro-Oncology Program. His philanthropy has helped secure research funding for the UCLA Neuro-Oncology Program for years to come.

The Art of the Brain also recognizes physician scientists who have made a difference in the brain cancer community by honoring them with Johnny Mercer Foundation Research Award. At the 2008 event, this research award was given to Dr. Donald P. Becker, Professor of Neurosurgery at UCLA. Dr. Becker is an established and well-respected neurosurgeon who has 40 years of experience in the neurological/surgical field. Over the span of his career, Dr. Becker has contributed vast amounts of knowledge and expertise in the neurosurgery/oncology fields. He has been principal investigator to many research projects involving brain tumors and other brain injuries. During his tenure at UCLA, Dr. Becker has been involved in developing cutting edge care for brain cancer patients for over 25 years. He was honored with the 2008 award for his dedication to his patients and contributions to clinical brain cancer research.

Those in attendance of the Gala were also treated to a reception including delectable hors d’oeuvres and treats provided by Barney’s Beanery, Buddha’s Belly, Dandy Don’s Ice Cream, Elixir G, Figi Water, Gelsons Markets, Good Gracious, Johnny Rockets, Kate Mantillini, Pure Cheesecakes, Stan’s Donuts, Trader Joes and Woodranch BBQ.

The Ninth Annual Gala raised a total of $382,037.99, with expenses totaling $58,536.01. Since 2000, Art of the Brain has provided funding for the training of several physician scientists who have developed research projects aimed at eradicating brain cancer. Money raised from the event will continue to fund breakthrough and novel brain cancer research at the UCLA Neuro-Oncology Program.

Art of the Brain and the UCLA Neuro-Oncology Program would not have reached such significant milestones in scientific research without the support of its friends, donors and sponsors.

LIFE SPONSORS  
Richard Dean Anderson  
Genentech, Inc.  
The Alex Demos Foundation  
The Johnny Mercer Foundation  

LEGACY AND LAUGHTER SPONSORS  
City National Bank  
Jennifer and Robert Lopata  
The Spiegelman Family and Beryl Companies  

COURAGE SPONSORS  
William and Joyce Bromiley  
Joan and Gerald Doren  
Gang Tyre Ramer and Brown  
Greenberg Traurig  
Judi and Roy Kaufman  

GRATITUDE SPONSORS  
Howard Bernstein and Bunny Wasser  
Marlene and David Capell  
Clint and Dina Eastwood  
Doris P. Haims  
Ann Ramer  
Mary and Peter Rooney  
Shamrock Holdings of California  
Mace Siegel  
The Carsey Family Foundation  
The Florence and Bernard B. Roth Family Foundation  
Gy and Jadi Waldron  
The Werner Family Foundation  

If you would like more information on Art of the Brain or would like to make a donation, please visit the Art of the Brain website at www.artofthebrain.org or call (310) 825-5074.
Ivy Foundation awards funding for novel Molecular Diagnostic Tools

The Ben and Catherine Ivy Foundation (Ivy Foundation) announced awards for five new patient-focused research projects for 2009, totaling more than $7 million focused on improving the survival and quality of life for all people with brain tumors. These funds are in addition to the $3.4 million awarded to brain tumor research projects by the Ivy Foundation earlier in 2008, its initial year of operation. For 2009, awards were granted to Allen Institute for Brain Science and the Swedish Neuroscience Institute; M.D. Anderson Cancer Center, University of Calgary, University of Pennsylvania and University of California, Los Angeles.

Research Projects were evaluated by The Ivy Foundation Scientific Reviewer Network, a group of researchers from academia and industry who volunteer their time to provide scientific critiques of research proposals. These independent reviewers ensure that the research projects funded by the Ivy Foundation will be of the highest merit and will have the greatest potential to impact patient care. “Given these tough economic times, we believe the influx of new multi-year projects funded by the Ivy Foundation can have a significant impact on advancing brain cancer research and, more importantly, the lives of patients,” said Dr. Catherine Nutt, Assistant Professor in Pathology, Harvard Medical School and Ivy Foundation Scientific Reviewer Network member.

Among the Ivy Foundation Award Recipients were UCLA’s Paul Mischel, MD and Tim Cloughesy, MD, and Jim Heath PhD from CALTECH for their work in the development and implementation of novel molecular diagnostic tools to guide combination therapy for malignant glioma patients.

The Mischel/Cloughesy/Heath collaboration hypothesizes that it is necessary to understand the signaling networks of multiple different components within a tumor in order to identify the most efficacious combination of targeted therapies for an individual patient with malignant glioma. Investigators propose to develop new ex-vivo tumor tissue- and serum-based molecular diagnostic approaches and test their utility as tools to guide the selection of and/or response to combination therapy.

The Ivy Foundation Awards represent research areas on the cutting edge of scientific inquiry, including biomarkers and signaling pathways, cancer stem cells, and gene expression profiling. “It was exciting to be a part of the review for these proposals – both because of the opportunity to work with highly reputable, careful and strategic reviewers representing both industry and academia; but also because the process resulted in five projects that hold the potential to move the needle forward in scientifically significant ways,” said Dr. David R. Parkinson, President and Chief Executive Officer, Nodality, Inc. and Ivy Foundation Scientific Reviewer Network member.

The Ivy Foundation is the nation’s largest privately funded foundation dedicated to improving survival and quality of life for people diagnosed with a brain tumor. Their approach is to fund research on gliomas leading to the development of better diagnostics and treatment for patients. In its inception year, 2008, The Ivy Foundation granted more than $10M in brain tumor research.

For more information, visit the Foundation’s web site at www.ivyfoundation.org.
Caregiver Support Group

Care giving is a human act of kindness required by all family members. Those faced with caring for a loved one with a cancer diagnosis can be especially difficult. UCLA Caregiver support group is designed to help and encourage those facing all support challenges, and help give the mental strength to deal with all of the emotions caregivers’ experience. If you would like to attend the next meeting please call (310) 825-6134 to RSVP.

Next Meeting Dates: April 9, 2009
May 14, 2009
June 11, 2009

Group meets at: UCLA Medical Center
200 Medical Plaza
Level B2, Room 265
Los Angeles, CA 90095

2009 Memorial Funds

<table>
<thead>
<tr>
<th>Name</th>
<th>Name</th>
<th>Name</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Katie Abbott</td>
<td>Susan Crane</td>
<td>Eliseha Goldstein</td>
<td>Basil Lombardo</td>
</tr>
<tr>
<td>Barbara Adeshek</td>
<td>H. Eugene Crawford</td>
<td>Armando Gonzalez</td>
<td>Stephanie Lopez</td>
</tr>
<tr>
<td>Elizabeth Adler</td>
<td>Marty Cronin</td>
<td>Edward Gorsuch</td>
<td>Stuart Lough</td>
</tr>
<tr>
<td>Arthur Allen, MD</td>
<td>Stephanie Crystal</td>
<td>Bill Grahn</td>
<td>Shirley Luedde</td>
</tr>
<tr>
<td>Terry Allen</td>
<td>Aida Dagort</td>
<td>Kevin M. Green</td>
<td>Gerald Lushing</td>
</tr>
<tr>
<td>June Anderson</td>
<td>Michael David</td>
<td>Patricia Grengs</td>
<td>Jack Maloney</td>
</tr>
<tr>
<td>Scott Anderson</td>
<td>Rod Davidson</td>
<td>Richard Haff</td>
<td>Tina Manaster</td>
</tr>
<tr>
<td>Ron Antoine</td>
<td>Alex Demos</td>
<td>Marie Halsey</td>
<td>Ron Martin</td>
</tr>
<tr>
<td>Tom Atkinson</td>
<td>Clark Desser</td>
<td>Jerry Harms</td>
<td>Saeko Mayeda</td>
</tr>
<tr>
<td>Adam Balch</td>
<td>Donna Dikes</td>
<td>Steven Harris</td>
<td>Jesse Mazon</td>
</tr>
<tr>
<td>Klaus Barth</td>
<td>Nancy Dorff</td>
<td>Russell Harrison</td>
<td>F. Leon McDonald</td>
</tr>
<tr>
<td>Lisa Barton</td>
<td>Florin Dumitra</td>
<td>Dolores Hernandez</td>
<td>James McDonald</td>
</tr>
<tr>
<td>Dorothy Beardman</td>
<td>Michael C. Dunn, MD</td>
<td>Jim Hernquist</td>
<td>Zane Melmed</td>
</tr>
<tr>
<td>Richard Beatty</td>
<td>Neil Elliot</td>
<td>Ralph Holt</td>
<td>Terry Miller</td>
</tr>
<tr>
<td>Jacqueline Bird</td>
<td>Yvonne Endicott</td>
<td>Arthur Hopwood</td>
<td>Sandra Morrissey</td>
</tr>
<tr>
<td>Tom Bishop</td>
<td>Renata Ernst</td>
<td>Roger Hughes, Sr.</td>
<td>Nellie Mortillaro</td>
</tr>
<tr>
<td>Paul Bleschmidt</td>
<td>Mark Estrin</td>
<td>Nancy Hunter</td>
<td>Ron Morton</td>
</tr>
<tr>
<td>Marvin Borden</td>
<td>John Falk</td>
<td>Ronn Iverson</td>
<td>Tamara Muinos</td>
</tr>
<tr>
<td>James Bouchard</td>
<td>John Jacob</td>
<td>John Jacobs</td>
<td>Prem Munjal</td>
</tr>
<tr>
<td>Kevin Boyle</td>
<td>Sharon Johl</td>
<td>Sharon Johl</td>
<td>Nancy Oark</td>
</tr>
<tr>
<td>Nancy Brodsky</td>
<td>Peter Joseph</td>
<td>Peter Joseph</td>
<td>Julietta C. Ortiz</td>
</tr>
<tr>
<td>Melvin Brody, MD</td>
<td>Richard Joswig</td>
<td>Richard Joswig</td>
<td>Jonathan Panzer</td>
</tr>
<tr>
<td>George R. Brown</td>
<td>Richard Justice</td>
<td>Richard Justice</td>
<td>Jean-Pierre Perez</td>
</tr>
<tr>
<td>John Cannon</td>
<td>Grannum Kaplan</td>
<td>Grannum Kaplan</td>
<td>Walter Peter</td>
</tr>
<tr>
<td>Gerald Chazan</td>
<td>Shodja Kargari</td>
<td>Shodja Kargari</td>
<td>Sylvia Philips</td>
</tr>
<tr>
<td>Walter Churgin</td>
<td>Kathy Kaufman</td>
<td>Kathy Kaufman</td>
<td>Joseph Pollard</td>
</tr>
<tr>
<td>Nina Citrin</td>
<td>Chris Knowles</td>
<td>Chris Knowles</td>
<td>Jeff Popovicv</td>
</tr>
<tr>
<td>James Clark</td>
<td>Erik Kroher</td>
<td>Erik Kroher</td>
<td>Susan Powell</td>
</tr>
<tr>
<td>Mary Clark</td>
<td>Kishan Kooner</td>
<td>Kishan Kooner</td>
<td>Mark Radcliffe</td>
</tr>
<tr>
<td>Richard Clayton</td>
<td>Elizabeth Korengold</td>
<td>Elizabeth Korengold</td>
<td>Theodore Reynolds</td>
</tr>
<tr>
<td>Jolly Cochetti</td>
<td>Bette Koupal</td>
<td>Bette Koupal</td>
<td>Kevin Riley</td>
</tr>
<tr>
<td>Nancy Confar</td>
<td>Marlin Kurle</td>
<td>Marlin Kurle</td>
<td>David Roesch</td>
</tr>
<tr>
<td>Joseph Copeland</td>
<td>William Lackey</td>
<td>William Lackey</td>
<td>Nancy Rose</td>
</tr>
<tr>
<td>Carol Corey</td>
<td>Gerald Lillis</td>
<td>Gerald Lillis</td>
<td>Gerald Roth</td>
</tr>
<tr>
<td>Theodore Coy</td>
<td>Lee Lobell</td>
<td>Lee Lobell</td>
<td>Catherine Rusher</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| For more information about any of our Memorial Funds or if you would like to create or donate to a Memorial Fund, please call Luzianne Dugenia at (310) 206-3610.
9th Annual Brain Tumor Conference
April 10th & 11th, 2009

Presented By:
University of California, Los Angeles; Neuro-Oncology

REGISTRATION DEADLINE
ONLINE & FAX: APRIL 7TH, 2009
MAIL-IN: APRIL 6TH, 2009

SEE INSIDE FOR DETAILS

FOR MORE INFORMATION PLEASE CALL 310.206.3610